Arrowhead Pharmaceuticals (ARWR) Set to Announce Earnings on Thursday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is anticipated to post its Q4 2026 results after the market closes on Thursday, November 12th. Analysts expect Arrowhead Pharmaceuticals to post earnings of ($1.52) per share and revenue of $61.18 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.13). Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The business had revenue of $75.25 million for the quarter, compared to the consensus estimate of $44.17 million. During the same quarter last year, the business posted ($1.26) EPS. The business’s revenue for the quarter was up 171.0% on a year-over-year basis. On average, analysts expect Arrowhead Pharmaceuticals to post ($3.62) EPS for the current fiscal year and ($4.73) EPS for the next fiscal year.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $61.65 on Thursday. The company has a market cap of $8.68 billion, a P/E ratio of -27.40 and a beta of 1.34. Arrowhead Pharmaceuticals has a 12-month low of $37.06 and a 12-month high of $95.49. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company’s fifty day moving average is $68.15 and its two-hundred day moving average is $71.55.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Royal Bank Of Canada restated an “outperform” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 31st. B. Riley Financial increased their price objective on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. raised their price objective on Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Morgan Stanley raised their price objective on Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Finally, HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $99.07.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the business’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total transaction of $173,920.00. Following the sale, the director owned 31,600 shares of the company’s stock, valued at $2,747,936. The trade was a 5.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael S. Perry sold 11,600 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. The trade was a 9.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.60% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes using RNA interference (RNAi). The company’s proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi-based therapies to specific tissues and reduce the production of targeted proteins.

Arrowhead’s research and development programs address a range of conditions, including cardiometabolic, pulmonary, liver, and central nervous system diseases.